NFKB1 and colitis: Wedelolactone markedly reduced the IL-1β-induced expression of COX-2, iNOS, TNF-α, and IL-6 in human chondrocytes by inhibiting NF-κB activation and further attenuated colonic inflammation in DSS-induced colitis via suppression of the IL-6/STAT3 axis [38].